Basket cover image
17 handpicked stocks

Beyond Buybacks: Companies Rewarding Investors

Charles Schwab's massive $20 billion stock buyback and dividend hike highlights a key indicator of corporate strength. This theme focuses on financially robust companies that are actively returning capital to their shareholders.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+7

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at जुलाई 27

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

SCHW

Charles Schwab Corp., The

SCHW

Current price

$95.76

Charles Schwab's $20 billion share repurchase authorization and 8% dividend increase demonstrates strong commitment to rewarding investors.

BRK.A

Berkshire Hathaway Inc.

BRK.A

Current price

$727,200.00

Berkshire Hathaway's disciplined capital allocation and strong cash generation make it a cornerstone holding for shareholder-focused investing.

PKW

Invesco BuyBack Achievers™ ETF

PKW

Current price

$105.15

This ETF focuses on companies with strong buyback programs, providing diversified exposure to shareholder-friendly businesses.

About This Group of Stocks

1

Our Expert Thinking

This group focuses on financially disciplined companies that actively return capital to shareholders through buybacks and dividends. These actions often signal management's confidence in their company's valuation and future earnings potential, making them attractive to investors seeking both growth and income.

2

What You Need to Know

These companies consistently generate strong free cash flow, enabling them to fund substantial stock buybacks and reliable dividend payments. This combination may appeal to investors looking for a blend of potential long-term growth and steady income from high-quality, mature businesses.

3

Why These Stocks

Each company was handpicked by professional analysts for their demonstrated commitment to shareholder-friendly policies. They represent businesses with strong balance sheets and a proven track record of returning capital to investors, offering a tactical approach to investing in corporate strength.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+67.73%

Group Performance Snapshot

67.73%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 67.73% over the next year.

12 of 15

Stocks Rated Buy by Analysts

12 of 15 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

💰

Cash Flow Champions

These companies generate strong free cash flow, giving them the financial flexibility to reward shareholders while still investing in growth. It's a sign of mature, well-managed businesses.

🎯

Management Confidence Signal

When companies buy back their own shares, it often signals that management believes their stock is undervalued. This vote of confidence can be a powerful indicator for investors.

Double Reward Potential

Many of these stocks offer both dividend income and potential price appreciation from buybacks. You could benefit from regular payments while your shares potentially become more valuable.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All Stock Groups

Frequently Asked Questions

Everything you need to know about the product and billing.